Is Globus Medical, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Globus Medical, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 36, a Price to Book Value of 1.98, and an EV to EBITDA ratio of 13.54. In comparison to peers, Masimo Corp. has a P/E of 179.74, while Lantheus Holdings, Inc. shows a more favorable P/E of 10.13, suggesting that Globus Medical's valuation is relatively high.
Recent performance against the S&P 500 further underscores this valuation concern, as the stock has returned -26.99% year-to-date compared to the index's gain of 16.30%. This stark contrast in returns highlights the challenges facing Globus Medical in the current market environment.